The Green Rush

Alternatively Speaking: Petr Sramek, Investing in Longevity Tech
Welcome to the Green Rush, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets, and culture, produced by KCSA Podcast Labs.
Today, we have a special episode featuring our newest production, Alternatively Speaking. In our debut season, we’re diving into a revolutionary concept in health span, longevity, and healthcare.
Hosts Phil Carlson and Anne Donohoe dive into the world of longevity technology with guest Petr Sramek, a visionary in the field of longevity tech. Petr is the co-founder, chairman, and managing general partner of the Longevitytech.fund, bringing over 33 years of experience as a serial tech entrepreneur to the table. His impressive resume includes being a former entrepreneur-in-residence at Singularity University and co-founder of theLongevityForum.eu.
Currently serving on the boards of several cutting-edge companies in the longevity sector, including Animal Biosciences in the U.S. and Age Curve in the U.K., Petr is dedicated to building the scientific, financial, and business infrastructure needed to accelerate the adoption of technologies that improve our health span.
Podcast Highlights:
- Introduction of Petr Sramek (00:11): Overview of Petr’s background as co-founder and chairman of the Longevity Tech Fund and his experience in technology entrepreneurship.
- Concept of “Healthy Longevity” (02:48): Explanation of the focus on expanding the healthy and active part of life rather than just extending the overall lifespan.
- Longevity Tech Fund Investment Strategy (17:35): Discussion of investment ticket sizes ranging from $100,000 to $600,000 and the fund’s approach to selecting companies.
- Longevity vs Traditional Biotech (29:34): Differentiation between longevity and traditional biotech investments, highlighting that aging is not classified as a disease.
- CRISPR and Gene Therapy in Longevity (37:33): Examination of CRISPR’s current limitations in longevity applications and the potential of gene therapy as a more relevant near-term approach.
- Advice for Investors and Companies (42:54): Guidance for retail investors interested in the longevity space and information on how companies can pitch to the Longevity Tech Fund.
- Personal Longevity Practices (47:30): Petr’s sharing of his own experiences with longevity interventions, including his epigenetic age results showing a 16-year difference from his chronological age.
Social Media:
- Petr’s LinkedIn: https://www.linkedin.com/in/petrsramek/
- X: https://x.com/petrsramekbench
Other Links/Mentions/Resources:
- Longevitytech.fund: https://www.longevitytech.fund/en/home
- Longevity Forum EU: https://www.longevityforum.eu/en/home
- HealthyLongevity.clinic: https://www.healthylongevity.clinic/
- Singularity University: https://www.su.org/
- AgeCurve: https://agecurve.co.uk/
- Animal Bioscience: https://animalbioscience.com/about-us/
Show Credits:
This episode was hosted by Phil Carlson and Anne Donohoe of KCSA Strategic Communications.
Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas.
You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing AltSpeaking@kcsa.com. You can also connect with us via our social channels:
- X: @KCSAPodcastLabs
- Instagram: @KCSAPodcastLabs
- LinkedIn: https://www.linkedin.com/company/kcsapodcastlabs/